
Hematologic Oncology Update · October 15 · 24 min
Chronic Lymphocytic Leukemia — Microlearning Activity 1
0:00 · Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL)-24:32
transcript
show notes
Featuring perspectives from Dr Catherine C Coombs, including the following topics:
- Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)
- Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10)
- Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL (10:05)
- Pirtobrutinib as first-line therapy for CLL and long-term safety data (15:22)
links1